Organic Chemical – Page 31

Delaware Court Ruling Paves Way for Aurion Biotech IPO, Alcon to Appeal Decision

11 months ago talkbio0Tagged Alcon, biotech, Bovichtus, Court of Chancery, Delaware, IPO, research, Reverse Stock Split, Series

Aurion Biotech, Alcon Research, IPO, Delaware Court of Chancery, reverse stock split, voting proxy, Series C consent rights

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

11 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

11 months ago talkbio0Tagged Agonist, enobosarm, GLP-1 receptor, Lean mass preservation, Obesity, sarcopenic, semaglutide, Wegovy, Weight Loss

Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist

Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon

11 months ago talkbio0Tagged Alcon, biotech, Bovichtus, Cell Therapy, Investments, IPO, Legal

Aurion Biotech, IPO, legal dispute, Alcon, cell therapy, biotech investment

Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication

11 months ago talkbio0Tagged Cardiovascular system, Discontinuation (procedure), Gout, Risk, scrutiny, Takeda, Uloric, United States Food and Drug Administration

Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny

Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement

11 months ago talkbio0Tagged addiction, Agreement, Crisis, multistate, Opioids, Pharma, Purdue, Recovery - action, Sackler family

Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs

Keytruda and Lenvima Combination Shows Mixed Results in Gastroesophageal Cancer Trial

11 months ago talkbio0Tagged Clinical Trials, Endpoints, Keytruda, Lenvima, Malignant neoplasm of cardioesophageal junction of stomach, Progression-Free Survival, Survival

Keytruda, Lenvima, gastroesophageal cancer, clinical trial, survival endpoints, progression-free survival, overall survival

Vigil’s TREM2-Targeted Alzheimer’s Treatment Advances to Phase II with Promising Early Results

11 months ago talkbio0Tagged Alzheimer 's disease, microglial-targeted, Neuroscience discipline, Phase 2 Clinical Trials, TREM2, VG-3927, Vigil

TREM2, Alzheimer’s disease, Vigil Neuroscience, VG-3927, Phase II clinical trial, microglial-targeted therapeutics

Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges

11 months ago talkbio0Tagged Achondroplasia, BioMarin, BridgeBio, CNP gene, Disorder of skeletal system, Dwarfism, genetic bone disorders, infigratinib, RBM-007, TransCon, Voxzogo

Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.

FDA Issues Boxed Warning for Anaphylaxis Risk with Multiple Sclerosis Drugs Copaxone and Glatopa

11 months ago talkbio0Tagged anaphylaxis, boxed, Cautionary Warning, Copaxone, glatiramer, Glatopa, Multiple Sclerosis, sandoz, Teva, United States Food and Drug Administration

FDA, boxed warning, anaphylaxis, multiple sclerosis, Copaxone, Glatopa, glatiramer acetate, Teva, Sandoz